In collaboration with Merck, the intravenous formulation of Cardiome's lead molecule, vernakalant (IV), was granted marketing approval in September, 2010 in the European Union, Iceland and Norway under the trademark BRINAVESSTM for rapid conversion of recent onset AF to sinus rythm in adults. It continues to expand into new markets around the world. + READ MORE
28 March, 2014
Cardiome Enters Agreement With Vianex S.A. To Commercialize Brinavess In Greece
27 March, 2014
Cardiome Reports Fourth Quarter And Full Year 2013 Financial Results
Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide values to patients, physicians and healthcare systems.